Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

A randomized controlled trial investigated use of sodium glucose cotransporter 2 inhibitors (SGLT2i) on top of standard care immunosuppression in lupus nephritis.

On July 16 2025, the Court of Appeal dismissed AstraZeneca’s appeal and upheld the first instance decision, finding that AstraZeneca’s compound ...

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March ...

Akums reports Q1 FY26 total income of Rs. 1,051 crore with 2.4% growth, 19% YoY adjusted EBITDA growth: Our Bureau, Bengaluru Tuesday, August 12, 2025, 15:30 Hrs [IST] Akums Drugs ...

In Q1 FY26, Akums reported total income of Rs. 1,051 crore, with healthy Adj EBITDA of Rs. 156 crore reflecting a robust 19.1 ...

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the ...